Melanoma Matters23 Des 2024

Ep 57: Best of 2024: ESMO

Summary

Voicing punctuation #2 ...

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss their second episode in the "Best of 2024" series and review the highlights from the 2024 ESMO Congress. They discuss the final analysis of CheckMate 067, long-term data from KEYNOTE 006, DMFS from NADINA, and the KEYMAKER U02 Substudy 02C. The conversation also covers results from CheckMate 76K and KEYNOTE 716, as well as an exploratory analysis from KEYNOTE 054.

Keywords

ESMO 2024, melanoma, CheckMate 067, KEYNOTE 006, NADINA, KEYMAKER U02, CheckMate 76K, KEYNOTE 716, KEYNOTE 054, immunotherapy

Takeaways

The final analysis of CheckMate 067 shows sustained overall survival benefit and demonstrates cure is possible.

Melanoma-specific survival is becoming a critical endpoint in trials.

Long-term data from KEYNOTE 006 confirms durable benefit of pembrolizumab.

The NADINA study presents sustained event-free survival & DMFS benefits.

KEYMAKER U02 highlights the potential of neoadjuvant platforms.

CheckMate 76K and KEYNOTE 716 show consistent results in adjuvant settings.

The importance of staffing clinical trials for long-term follow-up is emphasized.

New endpoints like PRFS2 are being explored in studies.

Chapters

00:00 Introduction and Holiday Reflections

02:46 Key Presentations from ESMO 2024

03:44 CheckMate 067 Final, 10-Year Analysis

07:38 KEYNOTE 006: 10-Year Data

12:34 NADINA DMFS

16:25 KEYMAKER U02: Substudy 02C (Umbrella Neoadjuvant Arms 4, 5, 6)

21:07 CheckMate 76K & KEYNOTE 716

25:03 KEYNOTE 054: 7 Year Follow-up

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(87)

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Jun 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Jun 1h 4min

Live from ASCO 2026: a preview

James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting.OptimUM-02ADAMKN-942Neoadjuvant pilot studies... and more

1 Jun 6min

Ep 81: IGNYTE trial (RP1 + nivo)

SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into cli...

13 Feb 32min

Ep 80: 2025 Holiday Special

SummaryHappy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music...

30 Des 202535min

Ep 79: coBRIM, COMBI-d 5-year follow-up

SummaryIn this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-...

29 Des 202536min

Ep 78 TRAILER: MEK inhibitor trials

Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

29 Des 20251min

Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)

SummarySo many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib...

29 Des 202537min